Dear world researchers,

 

In Japan, a camostat clinical trial plan for COVID-19 was published in November. 

Reference:

Yohei Doi. Pharmacotherapy and clinical trial. Journal of Japanese Society of Internal Medicine. 2020;109:2319-22 (in Japanese). 

 

① Ono Pharmaceutical Co., Ltd., which developed the camostat, is considering an in-house clinical trial. 

Release date: November 9, 2020 

Phase III: Clinical Trial Overview 

Study Design: Placebo-controlled, double-blind, randomized controlled trial 

Dosage: Camostat 600 mg or placebo orally administered 4 times daily 

Scheduled number of subjects: 110 

https://www.ono.co.jp/jpnw/PDF/n20_1109_3.pdf 

 

② The International University of Health and Welfare is planning an RCT to examine the combined effects of camostat and other existing drugs (Favipiravir and Ciclesonide). 

Release date: November 11, 2020 

https://jrct.niph.go.jp/latest-detail/jRCTs031200196 

 

These are all for the information at this time. 

December 16, 2020

Yoshiharu Uno, MD, PhD
Office Uno Column